22,239
Total Claims
$4.4M
Drug Cost
2,749
Beneficiaries
$1,597
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+5%
Cost per patient vs peers
$1,597 vs $1,524 avg
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 18,701 claims · $557K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,816 | $2.1M |
| Rivaroxaban | 490 | $582K |
| Sacubitril/Valsartan | 339 | $445K |
| Evolocumab | 147 | $218K |
| Ticagrelor | 248 | $218K |
| Alirocumab | 79 | $115K |
| Droxidopa | 20 | $80K |
| Metoprolol Succinate | 2,345 | $51K |
| Empagliflozin | 29 | $42K |
| Dapagliflozin Propanediol | 35 | $38K |
| Flecainide Acetate | 527 | $36K |
| Valsartan | 738 | $27K |
| Ranolazine | 115 | $23K |
| Clopidogrel Bisulfate | 1,355 | $23K |
| Atorvastatin Calcium | 1,695 | $22K |
Prescribing Profile
75
Unique Drugs
$3.2M
Patient Profile
75
Avg Age
48%
Female
1.56
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data